David Gershenson on Challenges to Advancing Treatment for Rare Ovarian Cancers

Video
Conference|Ovarian Cancer National Conference

David Gershenson, M.D., of MD Anderson Cancer Center, explains the difficulty of advancing treatment of rare ovarian cancers: malignant ovarian germ cell tumors, sex cord stromal tumors, and types of epithelial tumors such as ovarian clear cell carcinoma, ovarian low-grade serous carcinoma, and mucinous tumors.

David Gershenson, M.D., of MD Anderson Cancer Center, explains the difficulty of advancing treatment of rare ovarian cancers: malignant ovarian germ cell tumors, sex cord stromal tumors, and types of epithelial tumors such as ovarian clear cell carcinoma, ovarian low-grade serous carcinoma, and mucinous tumors. With such a low number of cases and not much interest from pharmaceutical companies, it is hard to conduct clinical trials in these areas.

Related Videos
Image of a woman with blond hai
Image of a man with rectangular glasses and short dark hair.
Image of a man with dark hair wearing a suit with a light blue tie.
Image of a woman with long dark hair.
Jessica McDade, B.S.N., RN, OCN, in an interview with CURE
Woman with dark brown hair and pink lipstick wearing a light pink blouse with a light brown blazer. Patients should have conversations with their providers about treatments after receiving diagnoses.
Man in a navy suit with a purple tie. Dr. Saby George talks to CURE about how treatment with Opdivo could mitigate disparities in patients with kidney cancer.
Related Content
image of a paper that says multiple myeloma with pills.

4-Drug Regimen Boosts Time to Progression in Newly Diagnosed Myeloma

Ryan Scott
June 8th 2024
Article

Sarclisa, Velcade, Revlimid and dexamethasone improved progression-free survival in patients with multiple myeloma who were not eligible for transplant.

Read More

cancer horizons logo: a white microphone on a navy blue background

Oncology Approvals, Psychological Outcomes for Survivors and an Ovarian Cancer Vaccine

Alex Biese;Brielle Benyon
March 11th 2024
Podcast

Last week we saw some FDA approvals come through, as well as research that explored the psychosocial outcomes of individuals who survived pediatric rhabdosarcoma.

Listen

Image of a doctor talking with a patient with penile cancer.

Keytruda Plus Chemo May Improve Penile Cancer Outcomes

Benjamin P. Saylor
June 6th 2024
Article

Keytruda plus platinum-based chemotherapy appeared to be safe and effective in treating penile squamous cell carcinoma.

Read More

cancer horizons image for podcast

Conference Highlights from the 2023 ASH Annual Meeting

Brielle Benyon;Alex Biese
December 14th 2023
Podcast

CURE® recently covered the 2023 American Society of Hematology Annual Meeting. In case you missed it, here is some news that came out of the conference that patients should know about.

Listen

Illustration of tumors in both lungs.

Opdivo Before and After Surgery Improves Event-Free Survival in NSCLC

Gina Mauro
June 4th 2024
Article

Some patients with stage 3 non-small cell lung cancer saw benefits from Opdivo plus chemotherapy followed by surgery then Opdivo, researchers found.

Read More

Image of lung cancer in the right lung.

Dato-DXd Improves Antitumor Intracranial Responses in NSCLC Subgroups

Kristie L. Kahl
June 4th 2024
Article

Dato-DXd was efficacious in patients with non-small cell lung cancer with brain metastases who have certain gene alterations, a phase 2 study showed.

Read More